{
    "id": 30717,
    "fullName": "TTN mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TTN mutant indicates an unspecified mutation in the TTN gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 7273,
        "geneSymbol": "TTN",
        "terms": [
            "TTN",
            "CMD1G",
            "CMH9",
            "CMPD4",
            "EOMFC",
            "HMERF",
            "LGMD2J",
            "LGMDR10",
            "MYLK5",
            "SALMY",
            "TMD"
        ]
    },
    "variant": "mutant",
    "createDate": "08/14/2019",
    "updateDate": "08/14/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18272,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a combined analysis of patients with melanoma treated with either Opdivo (nivolumab), Keytruda (pembrolizumab), Yervoy (ipilimumab), or Tremelimumab showed patients with mutant TTN versus those without mutant TTN had a greater overall survival (691 days vs 325 days, respectively) (PMID: 31092729).",
            "molecularProfile": {
                "id": 32956,
                "profileName": "TTN mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16089,
                    "pubMedId": 31092729,
                    "title": "Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18273,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a combined analysis of patients with melanoma treated with either Opdivo (nivolumab), Keytruda (pembrolizumab), Yervoy (ipilimumab), or Tremelimumab showed patients with mutant TTN versus those without mutant TTN had a greater overall survival (691 days vs 325 days, respectively) (PMID: 31092729).",
            "molecularProfile": {
                "id": 32956,
                "profileName": "TTN mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16089,
                    "pubMedId": 31092729,
                    "title": "Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18275,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a combined analysis of patients with melanoma treated with either Opdivo (nivolumab), Keytruda (pembrolizumab), Yervoy (ipilimumab), or Tremelimumab showed patients with mutant TTN versus those without mutant TTN had a greater overall survival (691 days vs 325 days, respectively) (PMID: 31092729).",
            "molecularProfile": {
                "id": 32956,
                "profileName": "TTN mutant"
            },
            "therapy": {
                "id": 1652,
                "therapyName": "Tremelimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16089,
                    "pubMedId": 31092729,
                    "title": "Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18274,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a combined analysis of patients with melanoma treated with either Opdivo (nivolumab), Keytruda (pembrolizumab), Yervoy (ipilimumab), or Tremelimumab showed patients with mutant TTN versus those without mutant TTN had a greater overall survival (691 days vs 325 days, respectively) (PMID: 31092729).",
            "molecularProfile": {
                "id": 32956,
                "profileName": "TTN mutant"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16089,
                    "pubMedId": 31092729,
                    "title": "Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32956,
            "profileName": "TTN mutant",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}